Search

Background: The use of intravenous (IV) iron sucrose was approved for the obstetric and gynecologic (OBGYN) population at our mother–child teaching hospital in 2006 for intolerance or nonresponse to oral iron supplements, contraindication to intramuscular (IM) iron, and rapid increase of the hemoglobin desired in iron-deficient patients. Objectives: ( a) To describe the indications and doses of IV iron sucrose used in OBGYN, ( b) to assess monitoring, and ( c) to describe the adverse effect profile. Methods: A retrospective study of patients admitted to the OBGYN wards with at least one prescription of IV iron from January 1, 2006, to March 31, 2010, was conducted. A standardized data collection sheet was used to record data. Results: A total of 164 prescriptions of IV iron were reviewed in 128 women. The indications for IV iron were anemia before delivery (n = 76), intolerance or no response to oral iron (n = 61), or intolerance or contraindication to IM iron (n = 27). Fourteen doses (9%) were appropriate, and the others were too low. Prior to prescription, ferritin or serum iron levels were assessed in 31% of women and hemoglobin electrophoresis in nearly all of Black or Asian women. One-week follow-up hemoglobin levels were measured after 66 prescriptions (40.2%). Adverse effects, mostly pain at the injection site, were reported in 18 (11%) occasions. Conclusions: IV iron is prescribed in OBGYN patients to obtain a rapid hemoglobin increase or when oral iron is not tolerated or inefficacious. The dose prescribed is generally too low, baseline essential testing often omitted, and appropriate follow-up monitoring incomplete. IV iron is well tolerated.

Resume Notre travail visait a comparer le taux de macrosomie et la moyenne de poids de naissance (en percentile) de nouveau-nes de meres diabetiques de type 1 (DT1) traitees par pompe a insuline sous-cutanee (PSC) ou par multi-injections quotidiennes d’insuline (MIQ). Il s’agit d’une etude retrospective, incluant les grossesses mono-fœtales de patientes DT1, dont l’issue de grossesse est survenue a plus de 16 semaines de grossesse, au CHU Sainte-Justine (Montreal, Quebec, Canada), entre le 1 er janvier 2000 et le 31 janvier 2009. Au total, 14 grossesses sous PSC et 94 sous MIQ ont ete evaluees. L’HbA 1c aux 1 er , 2 e et 3 e trimestres de grossesse n’etait pas significativement differente entre les groupes PSC et MIQ. Le percentile des poids de naissance (92±11 versus 77 ± 26) et le taux de macrosomie (71,4% versus 42,6%, respectivement) etaient significativement plus eleves dans le groupe PSC ( p